Sector News

Valeant starts $500M in Salix cost-cutting with 250 layoffs

April 7, 2015
Life sciences
After closing its deal for Salix Pharmaceuticals, Valeant wasted no time getting down to business with the cost-cutting it’s known for. And now, North Carolina’s Triangle area has another 250-plus pharma layoffs to add to a growing list.
 
Valeant will send 258 Salix staffers packing, the Triangle Business Journal reports–an announcement that came one day after the companies officially tied the knot. The job-shedding will begin this week and carry on through Oct. 30, with the cuts hitting a wide range of job functions.
 
One area that’s safe, though, is specialty sales. After signing their original pact in February–a $10 billion offer that the Canadian pharma upped to $15.8 billion after pressure from rival bidder Endo–Valeant CEO J. Michael Pearson acknowledged that he’d need that award-winning sales force and Salix’s hospital, key account and field reimbursement teams to help his company foray into the GI arena.
 
“We believe Salix’s sales force is, by far, the strongest in the GI space and it has been a key part of their success,” he told investors on a conference call, noting later that, “we believe these customer-facing roles have played and will play a huge role in the success of the company.”
 
The layoffs are part of a cost-savings drive that will top $500 million if Pearson gets his way. As Evercore ISI analyst Umer Raffat pointed out in a February note to clients, that equates to about 75% of Salix’s SG&A and R&D expenses. But that kind of penny-pinching is par for the course for Valeant, whose business model relies on wringing money out of plentiful acquisitions. Last month, it did the same at Dendreon, chopping 77 positions from the bankrupt oncology outfit it picked up shortly before Salix.
 
Meanwhile, though, it’s a tough time to be a Triangle pharma staffer, the TBJ points out. More than 1,000 industry employees have recently been dismissed, thanks to Hospira–which Pfizer agreed to buy up earlier this year–and GlaxoSmithKline, which is wielding the ax to compensate for lost sales of fading blockbuster Advair.
 
By Carly Helfand
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).